Nirmal Rajasekaran
Overview
Explore the profile of Nirmal Rajasekaran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mekonnen N, Yang H, Rajasekaran N, Song K, Choi Y, Shin Y
Transl Oncol
. 2024 Dec;
51:102204.
PMID: 39631207
MYC amplification is disproportionally elevated in triple-negative breast cancer (TNBC) compared to other subtypes of breast cancer. Indeed, MYC has long been considered an undruggable oncogene using conventional drug design...
2.
Song K, Lee H, Jia L, Chelakkot C, Rajasekaran N, Shin Y
Mol Cells
. 2022 Jun;
45(6):413-424.
PMID: 35680374
Suppressor of mothers against decapentaplegic homolog (SMAD) 4 is a pluripotent signaling mediator that regulates myriad cellular functions, including cell growth, cell division, angiogenesis, apoptosis, cell invasion, and metastasis, through...
3.
Song K, Rajasekaran N, Chelakkot C, Lee H, Paek S, Yang H, et al.
Pharmaceuticals (Basel)
. 2021 Oct;
14(10).
PMID: 34681284
Aerobic glycolysis in cancer cells, also known as the Warburg effect, is an indispensable hallmark of cancer. This metabolic adaptation of cancer cells makes them remarkably different from normal cells;...
4.
Liu J, Rajasekaran N, Hossain A, Zhang C, Guo S, Kang B, et al.
Pharmaceuticals (Basel)
. 2021 Aug;
14(8).
PMID: 34451816
Fulvestrant-3-boronic acid (ZB716), an oral selective estrogen receptor degrader (SERD) under clinical development, has been investigated in ADME studies to characterize its absorption, metabolism, and pharmacokinetics. ZB716 was found to...
5.
Rajasekaran N, Song K, Lee J, Wei Y, Erkin O, Lee H, et al.
Int J Mol Sci
. 2021 Jun;
22(11).
PMID: 34070531
SMAD4, a key regulator of transforming growth factor-β (TGF-β) signaling, plays a major role in cell growth, migration, and apoptosis. In particular, TGF-β/SMAD induces growth arrest, and SMAD4 induces the...
6.
Jayamohan S, Kannan M, Moorthy R, Rajasekaran N, Jung H, Shin Y, et al.
Front Oncol
. 2021 May;
11:694442.
PMID: 34055655
[This corrects the article DOI: 10.3389/fonc.2019.00847.].
7.
Yang H, Park H, Lee Y, Choi J, Kim T, Rajasekaran N, et al.
Biomolecules
. 2020 Jan;
10(1).
PMID: 31905631
Most malignant tumors originate from epithelial tissues in which tight junctions mediate cell-cell interactions. Tight junction proteins, especially claudin-3 (CLDN3), are overexpressed in various cancers. Claudin-3 is exposed externally during...
8.
Jayamohan S, Kannan M, Moorthy R, Rajasekaran N, Jung H, Shin Y, et al.
Front Oncol
. 2019 Sep;
9:847.
PMID: 31552174
Cervical Cancer (CC) is a highly aggressive tumor and is one of the leading causes of cancer-related deaths in women. miR-375 was shown to be significantly down-regulated in cervical cancer...
9.
Lee S, Son W, Yang H, Rajasekaran N, Kim S, Hong S, et al.
Front Pharmacol
. 2019 Feb;
9:1568.
PMID: 30733680
The glycoengineering approach is used to improve biophysical properties of protein-based drugs, but its direct impact on binding affinity and kinetic properties for the glycoengineered protein and its binding partner...
10.
Wang L, Wu C, Rajasekaran N, Shin Y
Cell Physiol Biochem
. 2018 Dec;
51(6):2647-2693.
PMID: 30562755
Cancer is a disease caused by the accumulation of genetic and epigenetic changes in two types of genes: tumor suppressor genes (TSGs) and proto-oncogenes. Extensive research has been conducted over...